<?xml version='1.0' encoding='utf-8'?>
<document id="28650129"><sentence text="In vitro efficacy and in silico analysis of cefixime-ofloxacin combination for Salmonella Typhi from bloodstream infection."><entity charOffset="44-52" id="DDI-PubMed.28650129.s1.e0" text="cefixime" /><entity charOffset="53-62" id="DDI-PubMed.28650129.s1.e1" text="ofloxacin" /><pair ddi="false" e1="DDI-PubMed.28650129.s1.e0" e2="DDI-PubMed.28650129.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28650129.s1.e0" e2="DDI-PubMed.28650129.s1.e1" /></sentence><sentence text="Recently, the cefixime-ofloxacin combination is approved by Drug Controller General of India to treat typhoid fever"><entity charOffset="14-22" id="DDI-PubMed.28650129.s2.e0" text="cefixime" /><entity charOffset="23-32" id="DDI-PubMed.28650129.s2.e1" text="ofloxacin" /><pair ddi="false" e1="DDI-PubMed.28650129.s2.e0" e2="DDI-PubMed.28650129.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28650129.s2.e0" e2="DDI-PubMed.28650129.s2.e1" /></sentence><sentence text=" We sought to evaluate the antimicrobial activity of cefixime-ofloxacin combination against Salmonella Typhi"><entity charOffset="53-61" id="DDI-PubMed.28650129.s3.e0" text="cefixime" /><entity charOffset="62-71" id="DDI-PubMed.28650129.s3.e1" text="ofloxacin" /><pair ddi="false" e1="DDI-PubMed.28650129.s3.e0" e2="DDI-PubMed.28650129.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28650129.s3.e0" e2="DDI-PubMed.28650129.s3.e1" /></sentence><sentence text="" /><sentence text="A total of 283 nonduplicate S" /><sentence text=" Typhi isolates collected during 2012-2014 were included in this study" /><sentence text=" Minimum inhibitory concentration (MIC) of cefixime and ofloxacin was determined by using broth microdilution method"><entity charOffset="43-51" id="DDI-PubMed.28650129.s7.e0" text="cefixime" /><entity charOffset="56-65" id="DDI-PubMed.28650129.s7.e1" text="ofloxacin" /><pair ddi="false" e1="DDI-PubMed.28650129.s7.e0" e2="DDI-PubMed.28650129.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28650129.s7.e0" e2="DDI-PubMed.28650129.s7.e1" /></sentence><sentence text=" Combinational testing was performed by using checkerboard assay" /><sentence text=" In checkerboard assay, synergistic activity was seen in 11% of isolates, while the majority of the isolate showed indifference and none of them showed antagonism" /><sentence text=" An in silico strategy, an alternative to the animal model, was carried out to understand drug interaction and toxicity" /><sentence text=" Molecular docking results elucidated that cefixime and ofloxacin are capable of inhibiting the cell wall synthesis and DNA replication, respectively"><entity charOffset="43-51" id="DDI-PubMed.28650129.s11.e0" text="cefixime" /><entity charOffset="56-65" id="DDI-PubMed.28650129.s11.e1" text="ofloxacin" /><pair ddi="false" e1="DDI-PubMed.28650129.s11.e0" e2="DDI-PubMed.28650129.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28650129.s11.e0" e2="DDI-PubMed.28650129.s11.e1" /></sentence><sentence text=" Computational ADMET analysis showed no toxicity and no drug-drug interaction between cefixime and ofloxacin"><entity charOffset="86-94" id="DDI-PubMed.28650129.s12.e0" text="cefixime" /><entity charOffset="99-108" id="DDI-PubMed.28650129.s12.e1" text="ofloxacin" /><pair ddi="false" e1="DDI-PubMed.28650129.s12.e0" e2="DDI-PubMed.28650129.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28650129.s12.e0" e2="DDI-PubMed.28650129.s12.e1" /></sentence><sentence text="" /><sentence text="Cefixime-ofloxacin combination could be effective against moderately susceptible fluoroquinolone S"><entity charOffset="0-8" id="DDI-PubMed.28650129.s14.e0" text="Cefixime" /><entity charOffset="9-18" id="DDI-PubMed.28650129.s14.e1" text="ofloxacin" /><pair ddi="false" e1="DDI-PubMed.28650129.s14.e0" e2="DDI-PubMed.28650129.s14.e0" /><pair ddi="false" e1="DDI-PubMed.28650129.s14.e0" e2="DDI-PubMed.28650129.s14.e1" /></sentence><sentence text=" Typhi but not fluoroquinolone-resistant isolates"><entity charOffset="15-30" id="DDI-PubMed.28650129.s15.e0" text="fluoroquinolone" /></sentence><sentence text="" /><sentence text="Cefixime-ofloxacin combination with no drug-drug interaction and nontoxic predicted through computational analysis did not show antagonism against S"><entity charOffset="0-8" id="DDI-PubMed.28650129.s17.e0" text="Cefixime" /><entity charOffset="9-18" id="DDI-PubMed.28650129.s17.e1" text="ofloxacin" /><pair ddi="false" e1="DDI-PubMed.28650129.s17.e0" e2="DDI-PubMed.28650129.s17.e0" /><pair ddi="false" e1="DDI-PubMed.28650129.s17.e0" e2="DDI-PubMed.28650129.s17.e1" /></sentence><sentence text=" Typhi in inÂ vitro" /><sentence text=" Although this study showed no adverse effects with the cefixime-ofloxacin combination, further studies on pharmacokinetic and pharmacodynamic (PK-PD) parameters of cefixime and ofloxacin combination are warranted"><entity charOffset="56-64" id="DDI-PubMed.28650129.s19.e0" text="cefixime" /><entity charOffset="65-74" id="DDI-PubMed.28650129.s19.e1" text="ofloxacin" /><entity charOffset="165-173" id="DDI-PubMed.28650129.s19.e2" text="cefixime" /><entity charOffset="178-187" id="DDI-PubMed.28650129.s19.e3" text="ofloxacin" /><pair ddi="false" e1="DDI-PubMed.28650129.s19.e0" e2="DDI-PubMed.28650129.s19.e0" /><pair ddi="false" e1="DDI-PubMed.28650129.s19.e0" e2="DDI-PubMed.28650129.s19.e1" /><pair ddi="false" e1="DDI-PubMed.28650129.s19.e0" e2="DDI-PubMed.28650129.s19.e2" /><pair ddi="false" e1="DDI-PubMed.28650129.s19.e0" e2="DDI-PubMed.28650129.s19.e3" /><pair ddi="false" e1="DDI-PubMed.28650129.s19.e1" e2="DDI-PubMed.28650129.s19.e1" /><pair ddi="false" e1="DDI-PubMed.28650129.s19.e1" e2="DDI-PubMed.28650129.s19.e2" /><pair ddi="false" e1="DDI-PubMed.28650129.s19.e1" e2="DDI-PubMed.28650129.s19.e3" /><pair ddi="false" e1="DDI-PubMed.28650129.s19.e2" e2="DDI-PubMed.28650129.s19.e2" /><pair ddi="false" e1="DDI-PubMed.28650129.s19.e2" e2="DDI-PubMed.28650129.s19.e3" /></sentence><sentence text="" /></document>